On the recordMarch 1, 2017
Reauthorizing improved generic and biosimilar user fee programs will lead to timelier approvals and lower drug costs. It's that simple.
Source
congress.govMichael Burgess: “Reauthorizing improved generic and biosimilar user fee programs will lead to timelier approvals and lower drug costs.…”
Editor's note · Context
Burgess emphasizes the importance of user fee reauthorization for drug cost reduction.
Share
More from Michael Burgess
Dec 17, 2024
This has all been so moving and so lovely, but if anyone tuned in late tonight in C-SPAN, they probably thought I passed because it really did sound like a eulogy. I am still here, and I will continue to text and call and inform everyone…
Dec 4, 2024
I am prepared for the gentleman to close. Mr. McGOVERN. Mr. Speaker, I yield myself the balance of my time to close. Mr. Speaker, let us talk about priorities. My Republican colleagues have theirs all screwed up, and I am being really kind…
Sep 24, 2024
By direction of the Committee on Rules, I call up House Resolution 1486 and ask for its immediate consideration. The Clerk read the resolution, as follows: H. Res. 1486 Resolved, That at any time after adoption of this resolution the…
Nov 13, 2024
By direction of the Committee on Rules, I call up House Resolution 1568 and ask for its immediate consideration. The Clerk read the resolution, as follows: H. Res. 1568 Resolved, That upon adoption of this resolution it shall be in order…
Other voices in this conversation
